{
 "name": "訊聯基因",
 "slug": "tw-4160",
 "aliases": [
  "訊聯基因數位股份有限公司",
  "GGA Corp.",
  "4160"
 ],
 "ticker": "4160",
 "industry": "生技醫療業",
 "website": "www.GGA.Asia",
 "summary": "訊聯基因（4160）是上櫃的生技醫療類股公司，2008 年成立，2012 年上櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "訊聯基因數位股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "英文簡稱",
   "value": "GGA Corp.",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心上櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "上櫃日期",
   "value": "2012-09-17",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "成立日期",
   "value": "2008-11-21",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "董事長",
   "value": "張漢東",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "總經理",
   "value": "康清原",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "實收資本額",
   "value": 280137340,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "公司網址",
   "value": "www.GGA.Asia",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_O"
  },
  {
   "claim": "月營收（2026-09）",
   "value": 48157,
   "unit": "新台幣千元",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of一致並保留；出表日1151017。僅更正source及補此note。"
  },
  {
   "claim": "月營收年增率（2026-09）",
   "value": 6.48,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of一致並保留；出表日1151017。僅更正source及補此note。"
  },
  {
   "claim": "累計營收年增率（2026 年 1 月至 09 月）",
   "value": 5.71,
   "unit": "%",
   "as_of": "2026-10-17",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap05_O",
   "note": "原檔二手來源不在白名單；本次回查官方115年09月營收申報，原claim/value/unit/as_of一致並保留；出表日1151017。僅更正source及補此note。"
  },
  {
   "claim": "主要產品／服務：DeepExoMir",
   "value": "自研演算法，協助尋找miRNA作用標靶及外泌體產品開發",
   "unit": "",
   "as_of": "2026-07-16",
   "source": "https://www.gga.asia/upload/img_page2/20260715/20260716%20GGA%E6%B3%95%E8%AA%AA%E7%B0%A1%E5%A0%B1.pdf",
   "note": "2026-07-16法說PDF第13頁；服務/研究工具，不宣稱臨床核准效益。"
  },
  {
   "claim": "主要產品／服務：BIOVIA GTD",
   "value": "生成式AI合併多因子優化之藥物研發方案",
   "unit": "",
   "as_of": "2026-07-16",
   "source": "https://www.gga.asia/upload/img_page2/20260715/20260716%20GGA%E6%B3%95%E8%AA%AA%E7%B0%A1%E5%A0%B1.pdf",
   "note": "2026-07-16法說PDF第6頁；服務/研究工具，不宣稱臨床核准效益。"
  },
  {
   "claim": "主要產品／服務：孕知因",
   "value": "420項遺傳疾病帶因篩檢",
   "unit": "",
   "as_of": "2026-07-16",
   "source": "https://www.gga.asia/upload/img_page2/20260715/20260716%20GGA%E6%B3%95%E8%AA%AA%E7%B0%A1%E5%A0%B1.pdf",
   "note": "2026-07-16法說PDF第21頁；服務/研究工具，不宣稱臨床核准效益。"
  },
  {
   "claim": "主要產品／服務：NIPT",
   "value": "80項單基因疾病檢測",
   "unit": "",
   "as_of": "2026-07-16",
   "source": "https://www.gga.asia/upload/img_page2/20260715/20260716%20GGA%E6%B3%95%E8%AA%AA%E7%B0%A1%E5%A0%B1.pdf",
   "note": "2026-07-16法說PDF第21頁；服務/研究工具，不宣稱臨床核准效益。"
  },
  {
   "claim": "主要產品／服務：PGTA（升級SNP分析）",
   "value": "胚胎檢測之PGTA服務，升級SNP分析",
   "unit": "",
   "as_of": "2026-07-16",
   "source": "https://www.gga.asia/upload/img_page2/20260715/20260716%20GGA%E6%B3%95%E8%AA%AA%E7%B0%A1%E5%A0%B1.pdf",
   "note": "2026-07-16法說PDF第21頁；服務/研究工具，不宣稱臨床核准效益。"
  },
  {
   "claim": "主要產品／服務：eCTD／EXTEDO",
   "value": "藥品查驗登記電子送件及服務支援方案",
   "unit": "",
   "as_of": "2026-07-16",
   "source": "https://www.gga.asia/upload/img_page2/20260715/20260716%20GGA%E6%B3%95%E8%AA%AA%E7%B0%A1%E5%A0%B1.pdf",
   "note": "2026-07-16法說PDF第7頁；服務/研究工具，不宣稱臨床核准效益。"
  },
  {
   "claim": "催化劑：eCTD",
   "value": "TFDA新成分新藥及生物藥品查驗登記申請全面採用eCTD｜2027-07-01｜已公告",
   "unit": "",
   "as_of": "2026-07-16",
   "source": "https://www.gga.asia/upload/img_page2/20260715/20260716%20GGA%E6%B3%95%E8%AA%AA%E7%B0%A1%E5%A0%B1.pdf",
   "note": "PDF第7頁引述TFDA政策2027年7月1日起實施；此為與公司eCTD服務相關之法規事件，不是公司收款或營收保證。"
  }
 ],
 "provided_by": "public_sources",
 "verified_at": "2026-10-22",
 "url": "https://drugnews.com.tw/companies/tw-4160.json",
 "generated_at": "2026-10-23T01:06:05.573Z"
}